Brief: Akari Therapeutics Files Prospectus Relates To Resale, By Selling Shareholders, Of Upto Total Of 642,753 ADS, Representing 1.3 Billion Ordinary Shares
20/10/2023 21:57
Oct 20 (Reuters) - Akari Therapeutics PLC AKTX.O :
* AKARI THERAPEUTICS: FILES PROSPECTUS RELATES TO RESALE, BY
SELLING SHAREHOLDERS, OF UPTO TOTAL OF 642,753 ADS, REPRESENTING
1.3 BILLION ORDINARY SHARES
Source text for Eikon: ID:
Further company coverage: AKTX.O
Recent news on Akari Therapeutics
See all newsBrief: Akari Therapeutics - Aktx-101 Demonstrates Robust Anti-Tumor Activity In Urothelial Cancer Preclinical Models
UK's Akari Therapeutics Q2 net loss widens on higher R&D for AKTX-101
Akari Therapeutics PLC reports results for the quarter ended June 30 - Earnings Summary
Akari Therapeutics PLC expected to post a loss of $1.40 a share - Earnings Preview
Brief: Akari Therapeutics Enters Strategic Research Collaboration With Whitehawk Therapeutics